Clinical trial · Interventional
Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer
Interest of Preoperative Immunonutrition in Liver Resection for Cancer
NCT02041871CI-TRIAL-00035231PROPILScompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study the efficacy of preoperative immunonutrition in reducing postoperative morbidity after liver resection for cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Elective Hepatectomy | — | UNRESOLVED | — |
| Hepatectomy | — | UNRESOLVED | — |
| Malignant Tumors | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oral immunonutrition | Dietary Supplement | — | UNRESOLVED |
| Placebo | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Impact control
- description
- ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
- interventionNames
- Dietary Supplement: Oral immunonutrition
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo
- interventionNames
- Dietary Supplement: Placebo
Primary outcomes (1)
- measure
- Overall complications classified in grade 2-3-4 or 5 by DINDO-CLAVIEN
- timeFrame
- In the first 30 postoperative days after Liver surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Non cirrhotic patient * Elective liver surgery for cancer (primary or secondary malignant tumours) * Hepatectomy including at least 1 segment or 3 wedge resections Exclusion Criteria: * Liver resection for benign lesions * Liver resection associated with biliary tract surgery * Liver resection associated with gastro-intestinal surgery * Cirrhosis, defined by transient elastography (Fibroscan®) or by liver biopsy * Renal failure * Pregnancy or nursing women * History of hypersensitivity or allergy to arginine, omega-3 fatty acids, or nucleotides * Inability to take oral nutrition * Mental condition rendering the subject unable to understand the nature, end-points and consequences of the trial
References
Publications (1)
- DERIVEDCiacio O, Voron T, Pittau G, Lewin M, Vibert E, Adam R, Sa Cunha A, Cherqui D, Schielke A, Soubrane O, Scatton O, Salloum C, Azoulay D, Benoist S, Goyer P, Vaillant JC, Hannoun L, Boleslawski E, Agostini H, Samuel D, Castaing D. Interest of preoperative immunonutrition in liver resection for cancer: study protocol of the PROPILS trial, a multicenter randomized controlled phase IV trial. BMC Cancer. 2014 Dec 18;14:980. doi: 10.1186/1471-2407-14-980. PMID 25523036